Distribution of five mutually exclusive groups of P53, PARP and FANCD2.

<p>Distribution of five mutually exclusive groups of P53, PARP, and FANCD2. 37 patients (22%) were positive for all three of the proteins.</p

Patients' Baseline Characteristics.

<p>Patients' Baseline Characteristics.</p

High Levels of PARP, FANCD2 and P53 on Risk of 3-Year Recurrence.

<p>*Adjusted for age, cancer status (grade, histology type and stage) at diagnosis and the presence of residual tumor at surgery.</p

The Associations of P53, BRCAness Profile and Residual Tumor with 3-year Recurrence-Free Survival.

<p>*Negative is defined as no or weak staining; positive is defined as moderate or strong staining.</p

Association between Early Recurrence and Positive P53, PARP, and FANCD2.

<p>Association between positive P53, PARP, and FANCD2 in patients with and without early recurrence. Patients with early recurrence at both 6 and 12 months after diagnosis were much more likely to have high levels of all 3 proteins (50% at 6 months and 41.2% at 12 months).</p

Kaplan-Meier Estimated 3-Year Recurrence-Free Survival Curves.

<p>Kaplan-Meier estimated 3-year recurrence-free survival curves. <b>A:</b> No difference in recurrence-free survival when each of the 5 mutually exclusive groups by expression of PARP, FANCD2, and P53 were examined independently. <b>B:</b> Patients positive for all three PARP, FANCD2, and P53 had lower recurrence-free survival compared to patients not positive for all three.</p

Immunocytochemistry.

<p>Immunocytochemistry.</p

Associations of PARP and/or FANCD2 with P53.

<p>Association between PARP, FANCD2, and P53. Patients with positive PARP or positive FANCD2 were more likely to have positive P53. Patients positive for both PARP and FANCD2 were statistically more likely to stain positive for P53.</p

Request for Community partnership in data resource licensing planning

<p>We write an open letter to the NIH Data Research Council to initiate a dialog regarding NIH decisions on data use agreements and licenses. We are members of NIH-funded research groups that collect and/or integrate biomedical data from diverse sources for the purpose of advancing diagnosis, prognosis, treatment selection, and mechanistic discovery. </p><p><br></p><p>We welcome additional signatories here:</p><p>https://docs.google.com/document/d/1fbwKxnPu5f1YXlMM6UMyfBqHx_Inz86tKzwRFO4W8jQ<br></p><br><p>Summary:</p><br><ul><li><p>The current diversity of data use agreements and licenses significantly hampers the ability to reuse and redistribute data in various informatics contexts.</p></li><li><p>We believe that any mandatory data licensing policy must also include a plan for ensuring access, sustainability, and data quality. </p></li><li><p>We request community partnership with NIH to develop common licensing and data reuse plans. </p></li></ul